Clinical Potential of miRNAs in Human and Infectious Diseases
DOI:
https://doi.org/10.13052/mct2052-8426.811Keywords:
micro-RNA, cancer, infectious diseases, parasites, Toxoplasma, Plasmodium, TheileriaAbstract
MicroRNAs (miRNAs) are small non-coding RNA molecules that play critical roles in human disease. Several miRnome profiling studies have identified miRNAs deregulated in cancer and infectious diseases and miRNAs are also involved in regulation of the host response to infection. Thereby, the usage of miRNAs as biomarkers and potential treatments for both human and infectious diseases is under development. This review will provide insights into the contribution of miRNAs to pathogenesis and disease development and will present a general outline of the potential use of miRNAs as therapeutic tools.
References
Carninci, P., J. Yasuda, and Y. Hayashizaki, Multifaceted mammalian transcriptome. Curr Opin Cell Biol, 2008. 20(3): p. 274–80.
Shamovsky, I. and E. Nudler, Gene control by large noncoding RNAs. Sci STKE, 2006. 2006(355): p. pe40.
Yazgan, O. and J.E. Krebs, Noncoding but nonexpendable: transcriptional regulation by large noncoding RNA in eukaryotes. Biochem Cell Biol, 2007. 85(4): p. 484–96.
Lee, R.C., R.L. Feinbaum, and V. Ambros, The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell, 1993. 75(5): p. 843–54.
Guil, S. and M. Esteller, DNA methylomes, histone codes and miRNAs:tying it all together. Int J Biochem Cell Biol, 2009. 41(1): p. 87–95.
Ma, F., et al., MicroRNA-466l upregulates IL-10 expression in TLR-triggered macrophages by antagonizing RNA-binding protein
tristetraprolin-mediated IL-10 mRNA degradation. J Immunol, 2010.184(11): p. 6053–9.
Hussain, M., et al., Wolbachia uses host microRNAs to manipulate host gene expression and facilitate colonization of the dengue vector Aedes aegypti. Proc Natl Acad Sci USA, 2011. 108(22): p. 9250–5.
Henke, J.I., et al., microRNA-122 stimulates translation of hepatitis C virus RNA. EMBO J, 2008. 27(24): p. 3300–10.
Alvarez-Garcia, I. and E.A. Miska, MicroRNA functions in animal development and human disease. Development, 2005. 132(21): p. 4653–62.
Bartel, D.P., MicroRNAs: genomics, biogenesis, mechanism, and function. Cell, 2004. 116(2): p. 281–97.
Baranwal, S. and S.K. Alahari, miRNA control of tumor cell invasion and metastasis. Int J Cancer, 2010. 126(6): p. 1283–90.
Esquela-Kerscher, A. and F.J. Slack, Oncomirs – microRNAs with a role in cancer. Nat Rev Cancer, 2006. 6(4): p. 259–69.
Eulalio, A., L. Schulte, and J. Vogel, The mammalian microRNA response to bacterial infections. RNA Biol, 2012. 9(6): p. 742–50.
Staedel, C. and F. Darfeuille, MicroRNAs and bacterial infection. Cell Microbiol, 2013. 15(9): p. 1496–507.
Cullen, B.R., Viruses and microRNAs: RISCy interactions with serious consequences. Genes Dev, 2011. 25(18): p. 1881–94.
LaMonte, G., et al., Translocation of sickle cell erythrocyte microRNAs into Plasmodium falciparum inhibits parasite translation and contributes to malaria resistance. Cell Host Microbe, 2012. 12(2):p. 187–99.
Fernandez-Hernando, C., et al., MicroRNAs in metabolic disease. Arterioscler Thromb Vasc Biol, 2013. 33(2): p. 178–85.
Plank, M., et al., Targeting translational control as a novel way to treat inflammatory disease: the emerging role of microRNAs. Clin Exp Allergy, 2013. 43(9): p. 981–99.
Shenouda, S.K. and S.K. Alahari, MicroRNA function in cancer: oncogene or a tumor suppressor? Cancer Metastasis Rev, 2009. 28(3–4):
p. 369–78.
Tao, G. and J.F. Martin, MicroRNAs get to the heart of development. Elife, 2013. 2: p. e01710.
Wang, W., E.J. Kwon, and L.H. Tsai, MicroRNAs in learning, memory, and neurological diseases. Learn Mem, 2012. 19(9): p. 359–68.
Calin, G.A. and C.M. Croce, MicroRNA signatures in human cancers. Nat Rev Cancer, 2006. 6(11): p. 857–66.
Garzon, R., G.A. Calin, and C.M. Croce, MicroRNAs in Cancer. Annu Rev Med, 2009. 60: p. 167–79.
Meng, F., et al., MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology, 2007. 133(2): p. 647–58.
Calin, G.A. and C.M. Croce, Chronic lymphocytic leukemia: interplay between noncoding RNAs and protein-coding genes. Blood, 2009.
(23): p. 4761–70.
Calin, G.A., et al., MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci USA, 2004.
(32): p. 11755–60.
Eis, P.S., et al., Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc Natl Acad Sci USA, 2005. 102(10): p. 3627–32.
Poliseno, L., et al., Identification of the miR-106b∼25 microRNA cluster as a proto-oncogenic PTEN-targeting intron that cooperates with its host gene MCM7 in transformation. Sci Signal, 2010. 3(117): p. ra29.
Volinia, S., et al., A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA, 2006.
(7): p. 2257–61.
Lee, E.J., et al., Expression profiling identifies microRNA signature in pancreatic cancer. Int J Cancer, 2007. 120(5): p. 1046–54.
Yanaihara, N., et al., Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell, 2006. 9(3): p. 189–98.
Bommer, G.T., et al., p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr Biol, 2007. 17(15): p. 1298–307.
Chang, T.C., et al., Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell, 2007. 26(5): p. 745–52.
Starczynowski, D.T., et al., Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype. Nat Med, 2010. 16(1):
p. 49–58.
Mongroo, P.S. and A.K. Rustgi, The role of the miR-200 family in epithelial-mesenchymal transition. Cancer Biol Ther, 2010. 10(3):
p. 219–22.
Gebeshuber, C.A., K. Zatloukal, and J. Martinez, miR-29a suppresses tristetraprolin, which is a regulator of epithelial polarity and metastasis. EMBO Rep, 2009. 10(4): p. 400–5.
Shaham, L., et al., MiR-125 in normal and malignant hematopoiesis. Leukemia, 2012. 26(9): p. 2011–8.
Sun, Y.M., K.Y. Lin, and Y.Q. Chen, Diverse functions of miR-125 family in different cell contexts. J Hematol Oncol, 2013. 6: p. 6.
Kumar, M., et al., MicroRNA let-7 modulates the immune response to Mycobacterium tuberculosis infection via control of A20, an inhibitor of the NF-kappaB pathway. Cell Host Microbe, 2015. 17(3): p. 345–56.
Izar, B., et al., microRNA response to Listeria monocytogenes infection in epithelial cells. Int J Mol Sci, 2012. 13(1): p. 1173–85.
Mun, J., et al., MicroRNA-762 is upregulated in human corneal epithelial cells in response to tear fluid and Pseudomonas aeruginosa antigens and negatively regulates the expression of host defense genes encoding RNase7 and ST2. PLoS One, 2013. 8(2): p. e57850.
Yang, K., et al., miR-155 suppresses bacterial clearance in Pseudomonas aeruginosa-induced keratitis by targeting Rheb. J Infect Dis,
210(1): p. 89–98.
de Vries, W. and B. Berkhout, RNAi suppressors encoded by pathogenic human viruses. Int J Biochem Cell Biol, 2008. 40(10): p. 2007–12.
Pedersen, I.M., et al., Interferon modulation of cellular microRNAs as an antiviral mechanism. Nature, 2007. 449(7164): p. 919–22.
Zeiner, G.M., et al., Toxoplasma gondii infection specifically increases the levels of key host microRNAs. PLoS One, 2010. 5(1): p. e8742.
Shapira, S., et al., Suppression of NF-kappaB activation by infection with Toxoplasma gondii. J Infect Dis, 2002. 185 Suppl 1: p. S66–72.
Cai, Y., et al., STAT3-dependent transactivation of miRNA genes following Toxoplasma gondii infection in macrophage. Parasit Vectors, 2013. 6: p. 356.
Cannella, D., et al., miR-146a and miR-155 delineate a MicroRNA fingerprint associated with Toxoplasma persistence in the host brain.
Cell Rep, 2014. 6(5): p. 928–37.
Coulson, R.M., N. Hall, and C.A. Ouzounis, Comparative genomics of transcriptional control in the human malaria parasite Plasmodium falciparum. Genome Res, 2004. 14(8): p. 1548–54.
Hall, N., et al., A comprehensive survey of the Plasmodium life cycle by genomic, transcriptomic, and proteomic analyses. Science, 2005. 307(5706): p. 82–6.
Rathjen, T., et al., Analysis of short RNAs in the malaria parasite and its red blood cell host. FEBS Lett, 2006. 580(22): p. 5185–8.
Wurtz, N., et al., cAMP-dependent protein kinase from Plasmodium falciparum: an update. Parasitology, 2011. 138(1): p. 1–25.
Cohen, A., V. Combes, and G.E. Grau, MicroRNAs and Malaria – A Dynamic Interaction Still Incompletely Understood. J Neuroinfect Dis,
6(1).
Mantel, P.Y., et al., Infected erythrocyte-derived extracellular vesicles alter vascular function via regulatory Ago2-miRNA complexes in
malaria. Nat Commun, 2016. 7: p. 12727.
Wang, Z., et al., Red blood cells release microparticles containing human argonaute 2 and miRNAs to target genes of Plasmodium falciparum. Emerg Microbes Infect, 2017. 6(8): p. e75.
Chamnanchanunt, S., et al., Downregulation of plasma miR-451 and miR-16 in Plasmodium vivax infection. Exp Parasitol, 2015. 155:
p. 19–25.
Delic, D., et al., Hepatic miRNA expression reprogrammed by Plasmodium chabaudi malaria. Parasitol Res, 2011. 108(5): p. 1111–21.
Hentzschel, F., et al., AAV8-mediated in vivo overexpression of miR-155 enhances the protective capacity of genetically attenuated malarial parasites. Mol Ther, 2014. 22(12): p. 2130–41.
Marsolier, J., et al., OncomiR addiction is generated by a miR-155 feedback loop in Theileria-transformed leukocytes. PLoS Pathog, 2013. 9(4): p. e1003222.
Gillan, V., et al., Characterisation of infection associated microRNA and protein cargo in extracellular vesicles of Theileria annulata infected leukocytes. Cell Microbiol, 2019. 21(1): p. e12969.
Haidar, M., et al., miR-126-5p by direct targeting of JNK-interacting protein-2 (JIP-2) plays a key role in Theileria-infected macrophage
virulence. PLoS Pathog, 2018. 14(3): p. e1006942.
Abelson, J.F., et al., Sequence variants in SLITRK1 are associated with Tourette’s syndrome. Science, 2005. 310(5746): p. 317–20.
Porkka, K.P., et al., MicroRNA expression profiling in prostate cancer. Cancer Res, 2007. 67(13): p. 6130–5.
Qi, J., et al., Circulating microRNAs (cmiRNAs) as novel potential biomarkers for hepatocellular carcinoma. Neoplasma, 2013. 60(2):
p. 135–42.
Wang, X.F., C.Z. Lu, and D.S. Xia, [Intravascular ultrasonic evaluation of poststenting atherosclerotic plaque redistribution and lumen reduction at the stent edge: does stent length matter?]. Zhonghua Xin Xue Guan Bing Za Zhi, 2008. 36(6): p. 481–4.
Biswas, S., MicroRNAs as Therapeutic Agents: The Future of the Battle Against Cancer. Curr Top Med Chem, 2018. 18(30): p. 2544–54.
Elfimova, N., et al., Circulating microRNAs: promising candidates serving as novel biomarkers of acute hepatitis. Front Physiol, 2012. 3:
p. 476.
Hu, W., et al., Functional miRNAs in breast cancer drug resistance. Onco Targets Ther, 2018. 11: p. 1529–41.
Li, Y.J., et al., Alterations of serum levels of BDNF-related miRNAs in patients with depression. PLoS One, 2013. 8(5): p. e63648.
Wang, J., et al., Circulating microRNAs are promising novel biomarkers for drug-resistant epilepsy. Sci Rep, 2015. 5: p. 10201.
Weir, D.W., A. Sturrock, and B.R. Leavitt, Development of biomarkers for Huntington’s disease. Lancet Neurol, 2011. 10(6): p. 573–90.
Dong, Y., et al., Prognostic significance of miR-126 in various cancers: a meta-analysis. Onco Targets Ther, 2016. 9: p. 2547–55.
Bader, A.G., D. Brown, and M. Winkler, The promise of microRNA replacement therapy. Cancer Res, 2010. 70(18): p. 7027–30.
Czech, M.P., MicroRNAs as therapeutic targets. N Engl J Med, 2006. 354(11): p. 1194–5.
Rupaimoole, R. and F.J. Slack, MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov, 2017. 16(3): p. 203–22.
Stenvang, J., et al., Inhibition of microRNA function by antimiR oligonucleotides. Silence, 2012. 3(1): p. 1.
Wiggins, J.F., et al., Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer Res, 2010. 70(14):
p. 5923–30.
Liu, C., et al., The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med, 2011. 17(2): p. 211–5.
Trang, P., et al., Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol Ther, 2011. 19(6): p. 1116–22.
Kota, J., et al., Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell, 2009. 137(6): p. 1005–17.
Cortez, M.A., et al., Therapeutic delivery of miR-200c enhances radiosensitivity in lung cancer. Mol Ther, 2014. 22(8): p. 1494–1503.
Calin, G.A., et al., MiR-15a and miR-16-1 cluster functions in human leukemia. Proc Natl Acad Sci USA, 2008. 105(13): p. 5166–71.
Ma, L., et al., Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nat Biotechnol, 2010. 28(4): p. 341–7.
Park, J.K., et al., miR-221 silencing blocks hepatocellular carcinoma and promotes survival. Cancer Res, 2011. 71(24): p. 7608–16.
Rupaimoole, R., et al., Hypoxia-upregulated microRNA-630 targets Dicer, leading to increased tumor progression. Oncogene, 2016. 35(33): p. 4312–20.
Correia, C.N., et al., Circulating microRNAs as Potential Biomarkers of Infectious Disease. Front Immunol, 2017. 8: p. 118.
Drury, R.E., D. O’Connor, and A.J. Pollard, The Clinical Application of MicroRNAs in Infectious Disease. Front Immunol, 2017. 8: p. 1182.
Jopling, C.L., et al., Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science, 2005. 309(5740): p. 1577–81.
Elmen, J., et al., Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver. Nucleic Acids Res, 2008. 36(4): p. 1153–62.
Ho, B.C., et al., Inhibition of miR-146a prevents enterovirus-induced death by restoring the production of type I interferon. Nat Commun, 2014. 5: p. 3344.
Tay, H.L., et al., Antagonism of miR-328 increases the antimicrobial function of macrophages and neutrophils and rapid clearance of non- typeable Haemophilus influenzae (NTHi) from infected lung. PLoS Pathog, 2015. 11(4): p. e1004549.
Alexander, M., et al., Exosome-delivered microRNAs modulate the inflammatory response to endotoxin. Nat Commun, 2015. 6: p. 7321.
Zhang, T., et al., Salmonella enterica serovar enteritidis modulates intestinal epithelial miR-128 levels to decrease macrophage recruitment via macrophage colony-stimulating factor. J Infect Dis, 2014. 209(12): p. 2000–11.
